Abstract: Compositions, formulations and methods bio-balance the pH of sterile, sodium chloride inhalation and pulmonary irrigation solutions, such that the solutions are bio-similar to the homeostatic pH state of the Human Airway Surface Liquid (ASL) at about 7.4. These solutions are sterile, non-pyrogenic, additive and preservative free, and provided in sterile unit-of-use, blow-fill-seal vials. These solutions are intended for use in the induction of sputum production where sputum production is indicated, such as with Cystic Fibrosis patients and Bronchoalveolar lavage procedures. The solutions can be provided in concentrations from about 0.045% to about 10% sodium chloride in USP/Sterile water. The sodium chloride solutions are homogenous mixtures that include sterile water, sodium chloride, and sodium bicarbonate as a buffer. The solutions are provided in saline concentrations from 0.45% to 10%, for example, concentrations of 0.9%, 3%, 3.5%, 6%, and 7% with a pH of 7.4.

Abstract: A comprehensive aerosol therapy for administration to a patient in need of treatment is provided. More particularly, the aerosol therapy kit provides a seamless conduit for a patient to receive in-office or hospital inhalation treatments and access to drugs and equipment for continuing home use.

Abstract: A composition for the treatment and prophylactic management of bacterial and fungal respiratory infections is provided. The composition may contain a combination of a quaternary ammonium compound and hypertonic saline to be administered to a patient in need thereof.

Abstract: The present invention provides compositions and methods for treating sore throat by reducing inflammation and clearing oral-pharyngeal mucus associated with sore throat comprising hypertonic saline and menthol.

Abstract: Sterile, preservative-free premeasured hypertonic saline solutions may be administered to individuals afflicted with cystic fibrosis to increase mucolciliary clearance and to improve lung function. In particular, a 7% hypertonic saline solution may be administered at least 2 times a day, using a jet and/or vibrating-mesh nebulizer to an individual afflicted with cystic fibrosis.

Abstract: The invention relates to a racemic epinephrine inhalation solution, system, kit, and method for the treatment of croup. In particular, the racemic epinephrine solution is premixed, sterile, premeasured single unit dose of racemic epinephrine for the treatment of croup. More particularly, the racemic inhalation solution is free of antimicrobial preservatives and other preservatives. Additionally, the invention also relates to a comprehensive kit to administer racemic epinephrine aerosol therapy for the treatment of croup. More particularly, the invention relates to an inhalation therapy kit to provide a seamless conduit for a patient to receive in-office or hospital inhalation treatments and access to drugs and equipment for continuing home use.

Abstract: A comprehensive aerosol therapy for administration to a patient in need of treatment is provided. More particularly, the aerosol therapy kit provides a seamless conduit for a patient to receive in-office or hospital inhalation treatments and access to drugs and equipment for continuing home use.

Abstract: The invention generally relates to a dose packaging system for the administration of a liquid formulation to a patient requiring load-dose titration therapy of a pharmaceutically active drug, such as steroid therapy. More particularly, the invention relates to a dose packaging system for administering titration therapy of liquid formulations to a patient which eliminates the disadvantages that are associated with cups, dosing spoons, calibrated oral syringes and bottles.